PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
树突状细胞(DC)疫苗在肿瘤免疫治疗中的疗效常因抗原交叉呈递(XPT)效率低下导致的免疫原性较弱而受到限制。
英文原题:Three-dimensional cell culture: Future scope in cancer vaccine development.
三维(3D)细胞培养技术在活力和功能方面优于2D方法,正被用于开发创新性癌症疫苗。
三维(3D)细胞培养技术在活力和功能性方面优于二维(2D)方法,正被用于开发创新性癌症疫苗。利用3D细胞培养可以构建在结构和功能上与实际肿瘤相似的肿瘤球体。这些球体疫苗已显示出优于基于2D细胞的疫苗的抗肿瘤免疫应答。利用3D细胞培养还可以更高效地制备树突状细胞疫苗。个性化癌症疫苗正在利用3D细胞培养进行开发,较2D方法具有显著优势。3D细胞培养更接近自然的条件可能促进在2D培养中不表达的肿瘤抗原的表达,并可能通过将肿瘤细胞与其他细胞类型共培养而实现更具靶向性的疫苗。采用3D细胞培养的先进癌症疫苗有望不久问世。
Three-dimensional (3D) cell culture techniques, which are superior to 2D methods in viability and functionality, are being used to develop innovative cancer vaccines. Tumor spheroids, which are structurally and functionally similar to actual tumors, can be developed using 3D cell culture. These spheroid vaccines have shown superior antitumor immune responses to 2D cell-based vaccines. Dendritic cell vaccines can also be produced more efficiently using 3D cell culture. Personalized cancer vaccines are being developed using 3D cell culture, providing substantial benefits over 2D methods. The more natural conditions of 3D cell culture might promote the expression of tumor antigens not expressed in 2D culture, potentially allowing for more targeted vaccines by co-culturing tumor cells with other cell types. Advanced cancer vaccines using 3D cell cultures are expected soon.
MEMBER ACCOUNT
登录成功会直接打开下一页。